Crossmark

Use of antiosteoporotic medication in the Danish ROSE population-based screening study

Crossref DOI link: https://doi.org/10.1007/s00198-019-04934-7

Published Online: 2019-03-26

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Høiberg, M. P. https://orcid.org/0000-0002-6375-9028
Rubin, K. H.

Holmberg, T.

Rothmann, M. J.

Möller, S.

Gram, J.

Bech, M.

Brixen, K.

Hermann, A. P.
Funding

Funding for this research was provided by:

Interreg 4A
License Information

Text and Data Mining valid from 2019-03-26
More Information

Article History

Received: 6 July 2018

Accepted: 5 March 2019

First Online: 26 March 2019

Compliance with ethical standards

:

: All authors have completed the authorship and disclosure form. S Möller, T Holmberg M Bech, J Gram, KH Rubin have no conflict of interest. MJ Rothmann has received speaker fee from Eli Lilly. M Hoiberg is a full-time employee of Boehringer-Ingelheim Norway KS (currently). AP Hermann serves on advisory boards for Eli Lilly, Amgen, and she has received research funding from Eli Lilly, speaker fee from Eli Lilly, GSK, Genzyme, Amgen; and K Brixen received funding from Merck, Sharpe, Dohme, Amgen, Novartis and NPS, all outside the submitted work.